Spinal muscular atrophy type 1 (SMA type 1) is a severe genetic disorder that destroys the nerve cells controlling voluntary movement in infants, typically causing noticeable weakness within the first six months of life. It accounts for about 60% of all SMA cases and occurs in roughly 1 in every 13,000 to 16,000 births. Without treatment, most children with SMA type 1 do not survive past age two, though new therapies introduced in recent years have begun to change that outlook significantly.
What Causes SMA Type 1
SMA type 1 is caused by a missing or mutated copy of a gene called SMN1, which produces a protein essential for the survival of motor neurons. These are the nerve cells in the spinal cord that send signals to muscles, telling them to contract. When the SMN1 gene doesn’t work, motor neurons gradually die, and the muscles they control weaken and waste away.
Humans carry a backup gene called SMN2 that is nearly identical to SMN1, but it has a small difference in its genetic code that causes it to produce only about 5% to 10% of the functional protein the body needs. The number of SMN2 copies a person carries is the single biggest factor in how severe their SMA becomes. Children with SMA type 1 typically have just one or two copies of SMN2, which means they produce the least amount of working protein. More copies of SMN2 generally lead to milder forms of the disease with later onset.
SMA is inherited in an autosomal recessive pattern, meaning a child must receive a faulty SMN1 gene from both parents to develop the condition. Parents who each carry one faulty copy usually have no symptoms themselves.
How SMA Type 1 Affects Infants
Symptoms appear within the first six months of life, and parents often notice them early. The hallmark sign is profound muscle weakness, sometimes described as “floppy baby” because of severely low muscle tone. Infants with SMA type 1 have limited head control, lack normal reflexes, and cannot sit without support. These motor milestones are never reached rather than lost, because the disease is already progressing before the infant would typically develop those abilities.
The weakness isn’t limited to the arms and legs. The muscles between the ribs (intercostal muscles) weaken while the diaphragm remains relatively spared, giving infants a characteristic bell-shaped chest and an unusual breathing pattern where the belly moves more than the chest. Swallowing becomes difficult, which can lead to choking, aspiration of food into the lungs, and failure to thrive. Even with modern treatments, swallowing problems persist in many children. In one clinical study, all treated children with SMA type 1 still showed measurable swallowing impairment, and nearly half required feeding through a tube.
Diagnosis and Newborn Screening
SMA type 1 can now be detected before symptoms appear through newborn screening programs. As of recently, all 50 U.S. states and Washington, D.C. screen newborns for SMA using a blood spot test that checks for the deletion of the SMN1 gene. This is a critical development because treatment is far more effective when it starts before motor neurons are lost.
When a newborn screen comes back positive, the next step is confirmatory genetic testing, which also determines the number of SMN2 copies the child carries. That copy number helps predict disease severity and guides treatment decisions. About 83% of specialty providers perform this confirmatory testing at the first clinic visit. Some infants are still diagnosed the traditional way, after parents or pediatricians notice weakness, low muscle tone, or breathing difficulties, followed by genetic testing to confirm.
What Happens Inside the Body
The core problem in SMA type 1 is the progressive loss of motor neurons in the front part of the spinal cord, a region called the ventral horn. These neurons are responsible for activating skeletal muscles throughout the body. Without enough SMN protein, these cells die at an accelerated rate. Research on fetuses with SMA type 1 has shown that the normal process of motor neuron pruning during development is prolonged, meaning more neurons die than should during the earliest stages of life.
The SMN protein plays a role in processing genetic instructions within cells, specifically in a step called RNA splicing. When SMN levels drop too low, this process goes wrong in motor neurons, which appear to be uniquely vulnerable. Other cell types can tolerate lower levels of SMN protein, which is why the disease primarily affects movement rather than cognition. Children with SMA type 1 are typically alert, socially engaged, and intellectually normal.
Respiratory and Feeding Challenges
Breathing and eating are the two most life-threatening aspects of SMA type 1. Weak respiratory muscles make it hard for infants to cough effectively, clear secretions, or take deep breaths. This leads to recurring respiratory infections, collapsed areas of lung tissue (atelectasis), and in some cases permanent lung damage called bronchiectasis. Many children require non-invasive ventilation, a mask or nasal interface that helps push air into the lungs, particularly during sleep.
In one study of treated SMA type 1 patients, about a third developed bronchiectasis, and all of those children had been hospitalized multiple times for respiratory infections. Even children receiving disease-modifying therapies often show ongoing respiratory muscle weakness, with gradual declines in lung capacity over time. Ventilatory support remains a reality for a significant number of these children.
Treatment Options
Three approved therapies now target the root cause of SMA by increasing the amount of functional SMN protein in the body. These treatments have transformed the outlook for children diagnosed early, though they do not cure the disease entirely.
The first approach is gene therapy, which delivers a working copy of the SMN1 gene directly into the child’s cells using a harmless virus as a carrier. One version is given as a single intravenous infusion for children under two years old. A newer formulation, approved in late 2025, is injected into the fluid surrounding the spinal cord in a single dose, regardless of the child’s weight. Both contain the same active ingredient and aim to restore the body’s ability to produce SMN protein on its own.
The other main treatment approach works by coaxing the SMN2 gene to produce more functional protein than it normally would. One is given as an injection into the spinal fluid, initially in a loading phase and then every few months for life. Another is taken daily as a liquid by mouth, making it easier to administer to young children at home.
Timing matters enormously. Children who begin treatment before symptoms appear, often identified through newborn screening, have dramatically better outcomes than those who start after significant motor neuron loss. In studies, children under two who received treatment showed improved survival compared to untreated children, but many still needed ventilatory support, suggesting that existing damage cannot be fully reversed.
Life Expectancy and Prognosis
Without treatment, SMA type 1 is fatal in early childhood. Historical data shows a median survival of roughly 8 to 25 months, with most untreated children dying before age two, primarily from respiratory failure. One large study found the median age at which untreated children either died or required permanent ventilation was 19 months.
Treatment has improved these numbers, but the degree of improvement depends heavily on when therapy begins and how much motor neuron damage has already occurred. Children born more recently, in an era of greater awareness and earlier intervention, show better survival than those born before screening and treatment became available. In one cohort study, median survival for SMA type 1 children born before 2011 was about six months, while those born after 2011 survived a median of 15 months, even without access to the newest gene therapies.
For children who receive treatment early, particularly those caught through newborn screening before symptoms develop, some are achieving milestones previously considered impossible for SMA type 1, including sitting independently and, in rare cases, walking. These outcomes are not universal, and many treated children still live with significant disability, but they represent a profound shift from the disease’s natural course.
Ongoing Care and Support
Even with disease-modifying therapy, children with SMA type 1 need a coordinated care team. Current best practice guidelines recommend a team that includes specialists in pulmonology, nutrition, orthopedic surgery, physical and occupational therapy, speech and feeding therapy, and mental health support for families. A care coordinator helps manage the complexity of appointments and interventions.
Motor function assessments are central to monitoring progress. Clinicians use standardized scales designed specifically for SMA infants, with scores ranging from 0 to 64 based on the child’s ability to perform specific movements. Untreated infants with SMA type 1 typically score around 21 on this scale. These assessments are repeated at regular intervals to track whether treatment is working and to guide decisions about additional support like bracing, seating systems, or respiratory equipment. Physical and occupational therapists play a key role not just in assessment but in helping children maximize the function they have, supporting positioning, joint health, and participation in daily activities.